Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
67.60
+2.32 (3.55%)
At close: Jan 21, 2026, 4:00 PM EST
67.53
-0.07 (-0.10%)
After-hours: Jan 21, 2026, 6:52 PM EST
Arrowhead Pharmaceuticals Employees
Arrowhead Pharmaceuticals had 711 employees as of September 30, 2025. The number of employees increased by 102 or 16.75% compared to the previous year.
Employees
711
Change (1Y)
102
Growth (1Y)
16.75%
Revenue / Employee
$1,166,594
Profits / Employee
-$2,294
Market Cap
9.29B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 711 | 102 | 16.75% |
| Sep 30, 2024 | 609 | 84 | 16.00% |
| Sep 30, 2023 | 525 | 128 | 32.24% |
| Sep 30, 2022 | 397 | 68 | 20.67% |
| Sep 30, 2021 | 329 | 97 | 41.81% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Techne | 3,100 |
| BioMarin Pharmaceutical | 3,040 |
| Jazz Pharmaceuticals | 2,800 |
| Axsome Therapeutics | 816 |
| Cytokinetics | 498 |
| Avidity Biosciences | 391 |
| Halozyme Therapeutics | 350 |
| Krystal Biotech | 275 |
ARWR News
- 1 day ago - Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results - Business Wire
- 9 days ago - Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 13 days ago - Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants - Business Wire
- 14 days ago - Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China - Business Wire
- 15 days ago - Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock - Business Wire
- 15 days ago - Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Interim Results From Obesity Candidates and Advances in Treatment Approaches Transcript - Seeking Alpha
- 15 days ago - Arrowhead Pharmaceuticals: More Questions Than Answers After Data Obesity Update - Seeking Alpha
- 15 days ago - Zepbound Boost Gets a Lift From Arrowhead's Drug. The Question Is Whether Patients Will Pay. - Barrons